Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
A new combo is showing promise where little else has worked. IDP-023, an allogeneic natural killer cell therapy, paired with isatuximab produced a 45% response rate in patients with daratumumab-refractory multiple myeloma — compared to 0% with isatuximab alone historically. The treatment was well tolerated, with no dose-limiting toxicities or treatment-related deaths reported.
For patients with multiple myeloma who've exhausted most treatment options — including CAR T-cell therapy and daratumumab — a new combination is offering a rare glimmer of hope. IDP-023, an off-the-shelf natural killer (NK) cell therapy, combined with isatuximab produced meaningful responses in a phase 1/2 first-in-human study presented at the 2026 SITC Annual Meeting.
IDP-023 uses a specialized subset of NK cells called g-NK cells, derived from donors previously exposed to cytomegalovirus (CMV). These cells are uniquely primed to destroy cancer cells and may also help reshape the tumor microenvironment — potentially making patients more responsive to future therapies like T-cell engagers.
By the Numbers:
Why it matters: This population — post-CAR T and post-T-cell engager — is growing as powerful therapies move earlier in treatment. A safe, effective off-the-shelf NK cell option could fill a critical gap for patients who currently have very few options left.
